UY27699A1 - Inhibidores. - Google Patents

Inhibidores.

Info

Publication number
UY27699A1
UY27699A1 UY27699A UY27699A UY27699A1 UY 27699 A1 UY27699 A1 UY 27699A1 UY 27699 A UY27699 A UY 27699A UY 27699 A UY27699 A UY 27699A UY 27699 A1 UY27699 A1 UY 27699A1
Authority
UY
Uruguay
Prior art keywords
lower alkyl
alkyl
optionally substituted
benzyl
phenyl
Prior art date
Application number
UY27699A
Other languages
English (en)
Inventor
David M Evans
Original Assignee
Ferreng B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferreng B V filed Critical Ferreng B V
Publication of UY27699A1 publication Critical patent/UY27699A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06078Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Compuestos de la fórmula general 1, o sales de los mismos aceptables para el uso farmacéutico, donde R1 se selecciona entre H, alquilo inferior, R4-CO, R4-O2CCH2, R5-OCO y R5-SO2; R2 se selecciona entre alquilo inferior, cicloalquilo, (C5-C12) cicioalquilalquilo opcionalmente sustituido con un grupo alquilo o alquiloxilo, aralquilo opcionalmente sustituido con hasta tres grupos seleccionados entre F, CI, Rr, I, OH, alquilo inferior, O-(alquilo inferior), O-bencilo, NH2, NO2, NH-acilo, CN y CF3, y aralquitoximetillo opcionalmente sustituido hasta tres grupos seleccionados entre F, CI, Br,OH, alquilo inferior y O-(alquilo inferior); o R1, y R2 son juntos un grupo seleccionado entre F, CI, Br, OH, alquilo inferior y O- (alquilo inferior); R3 se selecciona entre H, OH y O- alquilo inferior,R4 se selecciona entre H, alquilo inferior y fenilo; y R5 se selecciona entre alquilo inferior, fenilo y bencilo. Los compuestos son útiles como composiciones farmacéuticas.
UY27699A 2002-03-08 2003-03-06 Inhibidores. UY27699A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0205527.5A GB0205527D0 (en) 2002-03-08 2002-03-08 Inhibitors

Publications (1)

Publication Number Publication Date
UY27699A1 true UY27699A1 (es) 2003-10-31

Family

ID=9932619

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27699A UY27699A1 (es) 2002-03-08 2003-03-06 Inhibidores.

Country Status (27)

Country Link
US (1) US7649000B2 (es)
EP (1) EP1483284B1 (es)
JP (1) JP4330450B2 (es)
KR (1) KR100974633B1 (es)
CN (1) CN1274713C (es)
AR (1) AR039868A1 (es)
AT (1) ATE333463T1 (es)
AU (1) AU2003208471B2 (es)
CA (1) CA2478099C (es)
DE (1) DE60306904T2 (es)
DK (1) DK1483284T3 (es)
EG (1) EG25482A (es)
ES (1) ES2264523T3 (es)
GB (1) GB0205527D0 (es)
HK (1) HK1072265A1 (es)
IL (2) IL163710A0 (es)
MX (1) MXPA04008523A (es)
MY (1) MY130830A (es)
NO (1) NO332678B1 (es)
NZ (1) NZ534891A (es)
PL (1) PL209670B1 (es)
PT (1) PT1483284E (es)
RU (1) RU2301225C2 (es)
TW (1) TWI283685B (es)
UY (1) UY27699A1 (es)
WO (1) WO2003076458A2 (es)
ZA (1) ZA200406856B (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4775259B2 (ja) 2004-03-31 2011-09-21 味の素株式会社 アニリン誘導体
CA2696208A1 (en) * 2007-08-21 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
GB0918924D0 (en) * 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
US9290485B2 (en) 2010-08-04 2016-03-22 Novartis Ag N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
GB2494851A (en) * 2011-07-07 2013-03-27 Kalvista Pharmaceuticals Ltd Plasma kallikrein inhibitors
US20140378474A1 (en) 2012-01-27 2014-12-25 Novartis Ag 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
WO2013111107A1 (en) 2012-01-27 2013-08-01 Novartis Ag Aminopyridine derivatives as plasma kallikrein inhibitors
GB201212081D0 (en) 2012-07-06 2012-08-22 Kalvista Pharmaceuticals Ltd New polymorph
PH12015501492A1 (en) 2013-01-08 2015-09-28 Kalvista Pharmaceuticals Ltd Benzylamine derivatives
GB201300304D0 (en) 2013-01-08 2013-02-20 Kalvista Pharmaceuticals Ltd Benzylamine derivatives
GB2510407A (en) 2013-02-04 2014-08-06 Kalvista Pharmaceuticals Ltd Aqueous suspensions of kallikrein inhibitors for parenteral administration
CN105452240B (zh) 2013-05-23 2018-06-26 卡尔维斯塔制药有限公司 杂环衍生物
CA2920815C (en) 2013-08-14 2021-09-21 Kalvista Pharmaceuticals Limited Inhibitors of plasma kallikrein
GB2517908A (en) * 2013-08-14 2015-03-11 Kalvista Pharmaceuticals Ltd Bicyclic inhibitors
TWI636047B (zh) 2013-08-14 2018-09-21 英商卡爾維斯塔製藥有限公司 雜環衍生物
US10294274B2 (en) * 2013-10-28 2019-05-21 Bicyclerd Limited Polypeptide ligands specific for plasma kallikrein
EP3102200B1 (en) 2014-02-07 2023-04-05 Exithera Pharmaceuticals Inc. Therapeutic compounds and compositions
GB201421088D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
GB201421085D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
BR112018074395A2 (pt) 2016-05-31 2019-03-06 Kalvista Pharmaceuticals Limited derivados de pirazol como inibidores de calicreína plasmática
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201609603D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
HRP20220367T1 (hr) 2017-11-29 2022-05-27 Kalvista Pharmaceuticals Limited Oblici za doziranje koji sadrže plazmatski kalikrein inhibitor
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
EP3873446A4 (en) 2018-10-30 2022-08-03 Exithera Pharmaceuticals Inc. THERAPEUTIC COMPOUNDS AND COMPOSITIONS
GB201910116D0 (en) 2019-07-15 2019-08-28 Kalvista Pharmaceuticals Ltd Treatments of hereditary angioedema
GB201910125D0 (en) 2019-07-15 2019-08-28 Kalvista Pharmaceuticals Ltd Treatments of angioedema
EP4010333A1 (en) 2019-08-09 2022-06-15 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
GB2591730A (en) 2019-12-09 2021-08-11 Kalvista Pharmaceuticals Ltd New polymorphs
GB201918994D0 (en) 2019-12-20 2020-02-05 Kalvista Pharmaceuticals Ltd Treatments of diabetic macular edema and impaired visual acuity
WO2021198534A1 (en) 2020-04-04 2021-10-07 Oxurion NV Plasma kallikrein inhibitors for use in the treatment of coronaviral disease
TW202228686A (zh) 2020-10-15 2022-08-01 英商卡爾維斯塔製藥有限公司 血管性水腫之治療
US20230381162A1 (en) 2020-10-23 2023-11-30 Kalvista Pharmaceuticals Limited Treatments of angioedema
WO2022172006A1 (en) 2021-02-09 2022-08-18 Kalvista Pharmaceuticals Limited Treatments of hereditary angioedema
WO2023002219A1 (en) 2021-07-23 2023-01-26 Kalvista Pharmaceuticals Limited Treatments of hereditary angioedema
WO2023144030A1 (en) 2022-01-31 2023-08-03 Oxurion NV Plasma kallikrein inhibitor therapy for anti-vegf sensitization
WO2023148016A1 (en) 2022-02-04 2023-08-10 Oxurion NV Biomarker for plasma kallikrein inhibitor therapy response
AU2023262237A1 (en) 2022-04-27 2024-10-31 Kalvista Pharmaceuticals Limited Formulations of a plasma kallikrein inhibitor
WO2024180100A1 (en) 2023-02-27 2024-09-06 Kalvista Pharmaceuticals Limited New solid form of a plasma kallikrein inhibitor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9019558D0 (en) * 1990-09-07 1990-10-24 Szelke Michael Enzyme inhibitors
AU2882792A (en) * 1991-10-23 1993-05-21 Procter & Gamble Company, The Tripeptide derivative anti-inflammatory agents
SE9301911D0 (sv) * 1993-06-03 1993-06-03 Ab Astra New peptide derivatives
GB9318637D0 (en) * 1993-09-08 1993-10-27 Ferring Res Ltd Enzyme inhibitors

Also Published As

Publication number Publication date
TW200403255A (en) 2004-03-01
WO2003076458A2 (en) 2003-09-18
GB0205527D0 (en) 2002-04-24
CA2478099C (en) 2011-10-04
AU2003208471B2 (en) 2006-09-28
WO2003076458A3 (en) 2003-11-06
AU2003208471A1 (en) 2003-09-22
EP1483284B1 (en) 2006-07-19
IL163710A (en) 2010-12-30
NO332678B1 (no) 2012-12-03
ZA200406856B (en) 2005-11-30
JP4330450B2 (ja) 2009-09-16
RU2004126610A (ru) 2005-05-27
AR039868A1 (es) 2005-03-09
ES2264523T3 (es) 2007-01-01
TWI283685B (en) 2007-07-11
HK1072265A1 (en) 2005-08-19
EG25482A (en) 2012-01-15
PT1483284E (pt) 2006-11-30
RU2301225C2 (ru) 2007-06-20
MY130830A (en) 2007-07-31
EP1483284A2 (en) 2004-12-08
CN1639186A (zh) 2005-07-13
DK1483284T3 (da) 2006-10-16
DE60306904D1 (de) 2006-08-31
NO20043695L (no) 2004-10-07
JP2005533750A (ja) 2005-11-10
CN1274713C (zh) 2006-09-13
PL209670B1 (pl) 2011-10-31
NZ534891A (en) 2006-03-31
US7649000B2 (en) 2010-01-19
CA2478099A1 (en) 2003-09-18
KR20040089705A (ko) 2004-10-21
MXPA04008523A (es) 2004-12-06
KR100974633B1 (ko) 2010-08-06
PL372977A1 (en) 2005-08-08
IL163710A0 (en) 2005-12-18
DE60306904T2 (de) 2007-02-08
ATE333463T1 (de) 2006-08-15
US20060052313A1 (en) 2006-03-09

Similar Documents

Publication Publication Date Title
UY27699A1 (es) Inhibidores.
AR106755A2 (es) Inhibidores pirrólicos de la proteína quinasa erk, síntesis e intermediarios de los mismos
AR077414A2 (es) Compuestos de piperazina como antagonistas de taquinina sus sales y solvatos composiciones farmaceuticas que lo contienen su uso y procesos para su preparacion
ATE338461T1 (de) Pyrazolpyrimidinfungizide
CO5261626A1 (es) Glutarimidas sustituidas, su preparacion, medicamentos que las contienen, y uso de las mismas para la fabricacion de medicamentos, especialemente inmunomoduladores, como asi tambien inhibidores de angiopatias y/o enfermedades hematologicas/oncologica
AR028914A1 (es) 2-guanidino-4-aril-quinazolinas como inhibidores de nhe-3
UY28565A1 (es) Nuevos compuestos
GEP20074148B (en) Pyrrolo-triazine aniline compounds useful as kinase inhibitors
DE602004016127D1 (de) Antagonisten der opioidrezeptoren
UY28946A1 (es) Compuestos de aril-y heteroaril-alquilanina que contienen pirazol, composiciones farmacéuticas que contienen los compuestos y nuevos productos químicos intermedios
AR047823A1 (es) Derivados de 1,2,3,4-tetrahidroisoquinolina sustituida
IL173810A0 (en) Imidazopyridine derivatives and pharmaceutical compositions containing the same
UY27853A1 (es) Difenilazetidinonas sustituidas en grupo acido, procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso.
UY27851A1 (es) Difenilazetidinonas sustituidas en anillo, procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso.
AR042362A1 (es) Derivados de 3h-quinazolin-4-ona, proceso de obtencion y composiciones farmaceuticas que los contienen
AR061835A1 (es) Derivados tetraciclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR049883A1 (es) Antagonistas de cgrp seleccionados, procedimientos para su preparacion, y su empleo como medicamentos
HRP20050390A2 (en) Substituted benzoxazinones and uses thereof
ECSP045420A (es) Derivados de benzoxazina como moduladores 5-ht6 y usos de los mismos
MXPA04003008A (es) Compuestos pirimidina de anillo fusionado alquinilado como inhibidores de metaloproteasa 13 de la matriz.
ES2557004T3 (es) Mejoras en o relacionadas con compuestos orgánicos
CO5690579A2 (es) Derivados de diarilcicloalquilo, metodo para su produccion y su uso como medicamentos
UY27980A1 (es) Indoles 2,7-sustituidos
PA8589801A1 (es) Aminoalcoxiindoles
CR9499A (es) Nuevos derivados de fenilpiridinilpiperazina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150413